Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

17.04 -2.64 (-13.41%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗

July 03, 2025

Via Benzinga

AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report ↗

July 03, 2025

While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that...

Via Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 01, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 30, 2025

Via ACCESS Newswire

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

June 30, 2025

From Summit Therapeutics Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 26, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 25, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 24, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 23, 2025

From Pomerantz LLP

Via GlobeNewswire

Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)

June 20, 2025

With clinical catalysts on the horizon and a seasoned biotech insider doubling down, Could Nuvectis Pharma (NASDAQ:NVCT)* Become the Next Summit Therapeutics (NASDAQ: SMMT)?

Via News Direct

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 20, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 18, 2025

From Pomerantz LLP

Via GlobeNewswire

2 Dividend Stocks to Buy and Never Sell ↗

June 18, 2025

Via The Motley Fool

Topics Lawsuit

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 15, 2025

From Pomerantz LLP

Via GlobeNewswire

Why Summit Therapeutics Stock Tanked Today ↗

June 11, 2025

Via The Motley Fool

This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

June 11, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Why Casey's General Stores Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗

June 10, 2025

Via Benzinga

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2025

From Summit Therapeutics Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 06, 2025

From Pomerantz LLP

Via GlobeNewswire

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

June 05, 2025

From Summit Therapeutics Inc.

Via Business Wire

2 Soaring Stocks Wth More Upside Potential ↗

June 05, 2025

Via The Motley Fool

3 No-Brainer Healthcare Stocks to Buy in June ↗

June 02, 2025

Via The Motley Fool

Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? ↗

June 02, 2025

Via The Motley Fool

Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio? ↗

June 01, 2025

11 large-cap stocks with worst performance in last week: SMMT, PDD, REGN, BAH, OKTA, DECK, CPRT, COO, TPL, HPQ, BURL. Mixed results, lowered forecasts.

Via Benzinga

Which stocks are experiencing notable movement on Friday? ↗

May 30, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Dow Edges Higher; Dell Shares Fall After Q1 Results ↗

May 30, 2025

Via Benzinga

Topics Stocks

Why Summit Therapeutics Plunged Today ↗

May 30, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 30, 2025

Via Benzinga

Top movers in Friday's session ↗

May 30, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.